Methods for treating patients with ocular comorbidities of an autoimmune disorder

Ophthalmic roflumilast administration directly addresses ocular comorbidities of autoimmune disorders, enhancing treatment efficacy and safety by reducing ocular symptoms and maintaining systemic treatment continuity.

WO2026064609A1PCT designated stage Publication Date: 2026-03-26IOLYX THERAPEUTICS INC
View PDF 5 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-09-19
Publication Date
2026-03-26

AI Technical Summary

Technical Problem

Existing treatments for ocular comorbidities of autoimmune disorders, such as dry eye disease and ocular pain, are inadequate and often exacerbate systemic autoimmune symptoms or interact negatively with other therapies, particularly in female patients, who are disproportionately affected.

Method used

Administering ophthalmic pharmaceutical compositions of roflumilast, a phosphodiesterase-4 inhibitor, directly to the eye to treat ocular comorbidities, allowing concurrent use of systemic autoimmune treatments without additional systemic medication, thereby avoiding complications and side effects.

Benefits of technology

Reduces ocular symptoms like dryness, discomfort, and pain, improves quality of life, and maintains systemic treatment efficacy while minimizing adverse effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025047142_26032026_PF_FP_ABST
    Figure US2025047142_26032026_PF_FP_ABST
Patent Text Reader

Abstract

Methods of administering ophthalmic pharmaceutical formulations of the phosphodiesterase-4 inhibitor, roflumilast, for treating patients with ocular comorbidities of autoimmune disorder, including dry eye disease. The methods include selecting a patient previously diagnosed with an autoimmune disorder and administering an ophthalmic pharmaceutical composition comprising roflumilast to the patient to treat the ocular comorbidity of the autoimmune disorder. The method can result in a reduction of a total lissamine green conjunctival staining score or a reduction in total corneal fluorescein staining score relative to baseline.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Compounds and methods

    US20140155381A1

  • Methods of treating ocular inflammatory diseases

    US20230090417A1

  • High concentration pharmaceutical compositions of roflumilast for ophthalmic delivery

    US20240115491A1

  • Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases

    US20250032468A1

  • Therapeutic agent for dry eye associated with sjogren's syndrome

    WO2016152821A1